On September 20, 2021 Ranok Therapeutics (Hangzhou) Co. Ltd., an emerging biopharmaceutical company focused on developing breakthrough therapies for cancer and other serious diseases, reported that the company will present at the 19th Annual Discovery on Target conference in Boston, MA, September 27-30, 2021 (Press release, Ranok Therapeutics, SEP 20, 2021, View Source [SID1234588025]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Kevin P. Foley, Ph.D., Co-founder and Chief Scientific Officer of Ranok Therapeutics, will present a talk entitled "Tumor-Targeted Protein Degradation via Chaperones", as part of the conference’s PROTACs and Targeted Protein Degradation track.
Ranok has developed a proprietary and innovative targeted protein degradation (TPD) platform technology, CHAMP (Chaperone-mediated Protein Degradation), that leverages Ranok’s founders’ expertise in protein homeostasis to take advantage of the cellular chaperone network, potentially improving drug safety and efficacy due to selective targeting of disease tissues. The Company announced a $40 million Series B financing in August 2021, bringing the total raised to date to over $50 million in funding.
Event: 19th Annual Discovery on Target Conference
Date: Tuesday, September 28, 2021
Time: 9:05 a.m. EDT
Venue: Sheraton Boston, Boston, MA and virtually
In addition, Ranok Therapeutics will be presenting at these upcoming events:
October 15, Sino-American Pharmaceutical Professionals Association (SAPA) China Annual Conference (Suzhou, China)
October 19, Advances in Protein Degradation Webinar Series(virtual)
October 28, 4th Annual Targeted Protein Degradation Summit (virtual)
December 7, The New York Academy of Sciences’ Targeted Protein Degradation: From Drug Discovery to the Clinic Symposium (virtual)